Denali Therapeutics (DNLI) Short term Debt (2022)

Denali Therapeutics (DNLI) reported Short term Debt of $4.4 million for Q4 2022, up 204.09% quarter-over-quarter from $1.4 million in Q3 2022.

Denali Therapeutics (DNLI) Short term Debt (2022) Analysis & Trends

Denali Therapeutics (DNLI) has 1 years of Short term Debt data on file, last reported at $4.4 million in Q4 2022.

Short term Debt for Q4 2022 came in at $4.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $4.4 million (changed N/A YoY), and the FY2022 annual result was $4.4 million, changed N/A from the prior year.
Short term Debt climbed to $4.4 million in Q4 2022 per DNLI's latest filing, from $1.4 million in the prior quarter.
Over five years, Short term Debt peaked at $4.4 million in Q4 2022 and troughed at $1.4 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Denali Therapeutics	4.35 Bn	4.35 Bn	-

Download Data